Should I Buy MDT? MDT 2026 Analysis

Should You Buy Medtronic PLC (MDT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

100.460

1 Day change

-0.33%

52 Week Range

106.330

Analysis Updated At

2026/01/26

Medtronic PLC (MDT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, recent product launch, and improving healthcare sector outlook make it a solid choice for long-term growth. Despite insider selling and cautious Congress trading activity, the overall fundamentals and market sentiment favor a buy decision.

Technical Analysis

The technical indicators for MDT are bullish. The MACD is positively expanding, the RSI is neutral at 64.722, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm an upward trend. The stock is trading above key support levels with resistance at 101.248 and 102.757, suggesting potential for further gains.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Medtronic's Sphere-360 catheter launch and CE Mark approval in Europe, which could drive revenue growth.
Strong financial performance in Q2 2026, with revenue up 6.64% YoY, net income up 8.19% YoY, and EPS up 8.08% YoY.
Positive analyst sentiment with multiple upgrades and increased price targets, reflecting confidence in the company's growth trajectory.
Hedge funds are significantly increasing their holdings, with a 167.88% increase in buying over the last quarter.

Neutral/Negative Catalysts

Insider selling has increased by 288.10% over the last month, which may indicate caution among company executives.
Congress trading data shows 4 sale transactions in the last 90 days, with no purchases, reflecting a cautious stance.
Stock trend analysis indicates a 40% chance of a -4.16% decline in the next week, suggesting short-term volatility.

Financial Performance

In Q2 2026, Medtronic reported strong financial results: revenue increased by 6.64% YoY to $8.96 billion, net income rose by 8.19% YoY to $1.37 billion, EPS grew by 8.08% YoY to $1.07, and gross margin improved to 60.67%, up 0.85% YoY. These metrics highlight the company's robust growth and profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is highly positive. Recent upgrades include Bernstein raising the price target to $112 and maintaining an Outperform rating, Barclays increasing the price target to $116 with an Overweight rating, and William Blair upgrading the stock to Outperform. Analysts highlight strong growth potential, new product launches, and improving sector dynamics as key drivers for Medtronic's future performance.

20 Analyst Rating

Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 111.76 USD with a low forecast of 102 USD and a high forecast of 120 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

9 Hold

0 Sell

Moderate Buy

Current: 100.790

Low

102

Averages

111.76

High

120

Current: 100.790

Low

102

Averages

111.76

High

120

Bernstein

Outperform

maintain

$111 -> $112

AI Analysis

2026-01-09

Reason

Bernstein

Price Target

$111 -> $112

AI Analysis

2026-01-09

maintain

Outperform

Reason

Bernstein raised the firm's price target on Medtronic to $112 from $111 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Barclays

Matt Miksic

Overweight

maintain

$111 -> $116

2026-01-08

Reason

Barclays

Matt Miksic

Price Target

$111 -> $116

2026-01-08

maintain

Overweight

Reason

Barclays analyst Matt Miksic raised the firm's price target on Medtronic to $116 from $111 and keeps an Overweight rating on the shares. The firm cites an increased target multiple for the boost to put the stock in line with the recent increase in peers.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDT

Unlock Now

MDT Should I Buy

MDT Should I Buy

Should You Buy Medtronic PLC (MDT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch